Uterine Fibroid

FDA: New assessment discourages morcellation for fibroids

December 19, 2017

An updated review of evidence by the US Food and Drug Administration (FDA) underscores concerns expressed in 2014 by the agency about use of laparoscopic power morcellators (LPM) for treatment of uterine fibroids. Plus: Prescription habits show ob/gyns not well informed about opioids, according to a study. Also: Does ADHD medication use during pregnancy increase risk of congenital malformations?

The economics of uterine fibroids

October 13, 2015

A study tabulates the direct and indirect costs.

Uterine fibroids: medical management options

March 01, 2015

For women in whom surgery is not recommended or necessary, treatment with the goal of symptom relief and size reduction can be achieved medically.

SMFM consult: Fibroids in pregnancy: Meaning and Management

December 05, 2014

Questions and answers from SMFM about the implications of uterine fibroids during pregnancy

Antiprogestin CDB-2914 promising for uterine fibroids (VIDEO)

September 04, 2014

William Fredette, MD, discusses the benefits of Antiprogestin CDB-2914 for reducing uterine fibroid size and bleeding, and improving quality of life for affected women, as reported in the journal Fertility and Sterility. Video provided by The Doctor's Channel.

The morcellation controversy: What’s next?

June 01, 2014

Institutions around the country have responded to an FDA advisory by discouraging or banning power morcellation of uterine fibroids. Innovative methods of contained morcellation are now called for.

Power morcellation for uterine fibroids: What you need to know

March 01, 2014

Gynecologic surgeons should give consideration to the balance of benefit and harm that accompanies laparoscopic tissue morcellation, in addition to exploring surgical alternatives and methods to mitigate complications.